SYNLAB

What SYNLAB does

SYNLAB is a European medical diagnostics laboratory services company founded in 1998 and headquartered in Augsburg, Germany. It operates a network of regional laboratories across 13 European countries (including Germany, France, Italy, Spain, Austria, Belgium, the Nordics, Czech Republic, Bulgaria, Croatia, and Estonia) and employs more than 10,000 staff. The company was acquired by Mars, Incorporated as part of a strategy to consolidate European clinical pathology capacity. Following the acquisition, SYNLAB divested its Spanish operations to Eurofins Scientific SE in 2025.

SYNLAB's core offering is fee-for-service diagnostic laboratory testing for physicians, practice teams, hospitals, corporate occupational health clients, and patients. The test portfolio spans general medicine, gynaecology, oncology, and human genetics, including proprietary services such as FH ALERT (an automated LDL-C threshold-based alert for familial hypercholesterinaemia, published in Scientific Reports), neoBona non-invasive prenatal testing (NIPT), and immunochemical faecal occult blood testing (iFOBT) for colorectal cancer screening at a self-pay rate of €11.66 per test. Supporting infrastructure includes the SYNconnect electronic physician-laboratory portal and the SYNLAB Academy, a continuing medical education platform led by Prof. Winfried März.

The business operates on a transaction-based fee-for-service model, with statutory health insurance reimbursement in Germany covering screening services such as iFOBT for eligible individuals from age 50. Pricing is set within the German GOÄ physician fee schedule framework, with private insurers typically covering costs under individual contracts. Medicover's Diagnostic Services division, in which the SYNLAB acquisition is a key contributor, achieved a 17.3% EBITDA margin in 2025 with double-digit growth across fee-for-service markets, targeting EUR 3.25 billion in revenue and EUR 600 million in adjusted organic EBITDA by 2028. The German legal entity, SYNLAB Holding Deutschland GmbH, operates under four Managing Directors and is registered at August-Wessels-Straße 13, 86156 Augsburg.

Name

SYNLAB

Legal name

SYNLAB Holding Deutschland GmbH

Website

https://synlab.de

Company type

Private

Founded year

1998

Operating status

Operating

Headcount range

5,001–10,000 employees

Short description

SYNLAB is a European medical diagnostics laboratory services company operating regional laboratories across 13 countries, providing fee-for-service routine and specialized testing (including FH ALERT, NIPT, and cancer screening) to physicians, hospitals, corporates, and patients, owned by Mars, Incorporated.

Ownership category

akta.pro rank

Product category

Medical Diagnostic Laboratory Services

NAICS

Medical Laboratories (621511), Medical and Diagnostic Laboratories (6215)

SIC

Services-Medical Laboratories (8071)

akta.pro primary industry

Reference & Esoteric Testing Laboratories (HLAFAMAJ)

akta.pro secondary industries

Genetic & Prenatal Testing Laboratories (HLAFAMAH), Toxicology & Therapeutic Drug Monitoring Laboratories (HLAFAMAF), Central Laboratory Services (Core Lab Operations) (HLAGAEAA)

Keywords

• Medical diagnostic services
• Clinical laboratory testing
• Human medicine diagnostics
• Veterinary diagnostic services
• Specialized laboratory analytics

Headquarters

HQ city

Augsburg

HQ country

Germany

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Technology or R&D, Infrastructure, Marketing or Sales, Supply Chain

Revenue model

1. Diagnostic Services - Fee-for-Service Laboratory Testing: SYNLAB operates a network of regional laboratories providing fee-for-service diagnostic testing to physicians, hospitals, and patients. Revenue is generated through laboratory test orders across routine and specialized diagnostics including clinical chemistry, genetics, oncology, and infectious disease. Medicover's Diagnostic Services division (which includes SYNLAB) achieved margins of 17.3% in fee-for-service markets in 2025.

Pricing tiers

Distribution channels4 records

Marketing channels5 records

Core offering

SYNLAB operates an extensive network of regional laboratories across Germany and Europe, providing fee-for-service medical diagnostic testing to physicians, hospitals, practice teams, companies and patients. The portfolio covers routine and specialized diagnostics across clinical chemistry, genetics, oncology, infectious disease, gynaecology and human genetics, complemented by proprietary services such as FH ALERT for familial hypercholesterinaemia detection, neoBona non-invasive prenatal testing, and immunochemical colorectal cancer screening (iFOBT).

Product overview

SYNLAB operates as a medical diagnostics laboratory services provider offering a portfolio of diagnostic products and services. The core offering is its Human Medicine Division (Humanmedizin), providing comprehensive laboratory testing services to physicians, medical practices, hospitals, and patients. Key products include FH ALERT (an automated alert system for familial hypercholesterinaemia detection), neoBona (non-invasive prenatal testing), and SYNconnect (electronic physician-laboratory communication). Educational services are delivered through the SYNLAB Akademie. The company also provides specialized diagnostic services including occupational medicine for companies and laboratory operations support for hospitals. The product ecosystem is designed to serve the entire healthcare chain from physicians ordering tests to patients receiving results, with digital communication tools facilitating connectivity between stakeholders.

Differentiator

Problem solved

Functional benefit

Brands

• FH ALERT: A diagnostic service that identifies patients with familial hypercholesterinemia (FH) by automatically generating an alert when LDL-C values exceed 190 mg/dl, supporting early detection and treatment of this genetic lipid disorder.
• SYNLAB Akademie
• neoBona

Products and services

• SYNLAB Human Medicine (Humanmedizin) Diagnostics
• SYNLAB Veterinary Diagnostics (Tiermedizin)
• neoBona® Non-Invasive Prenatal Test (NIPT)
• iFOBT Colorectal Cancer Screening
• FH ALERT (Familial Hypercholesterinaemia Detection Service)
• Hospital Laboratory Operations Support
• Occupational Health Services for Companies
• Individual Patient Health Services

Quantifiable outcome

• FH ALERT identified FH patients at approximately 10x the rate of existing FH screening approaches in clinical practice
• +3 more outcomes

Segments5 records

Ideal customer profiles5 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature5 records

Partnerships

Two partnerships are on record, tiered minor and core.

• Eurofins Scientific SEminorStrategic or Co-development Partner · 1 January 2025Eurofins acquired SYNLAB's clinical diagnostics operations in Spain, completing this transaction in FY 2025 as part of 40 business combinations Eurofins completed during the year. This represents a divestiture by SYNLAB of its Spanish operations, with SYNLAB exiting its diagnostic presence in Spain.
• Mars, IncorporatedcoreStrategic or Co-development Partner · 1 January 2025Mars acquired SYNLAB as part of its strategy to consolidate presence in European clinical pathology markets. This represents a significant ownership change, with SYNLAB becoming part of Mars' broader diagnostic laboratory footprint alongside Cerba HealthCare, consolidating SYNLAB within Mars' portfolio of diagnostic services providers.

Scale indicators3 records

Recent moves6 records

Expansion highlights6 records

Direct peers

• Cerba HealthCare: Cerba HealthCare is a European reference and specialty clinical pathology laboratory group, also owned by Mars, Incorporated, making it a sister company to SYNLAB under the same parent. The two operate complementary specialty and routine testing networks across Europe.
• Unilabs: Unilabs is a major European clinical diagnostics and specialty testing provider headquartered in Switzerland, operating across 16+ countries. It directly competes with SYNLAB in routine and specialty testing, particularly in Western and Northern Europe.
• Sonic Healthcare: Sonic Healthcare is a global medical diagnostics company with a strong European laboratory footprint (including Germany, Switzerland, Belgium, the UK, and Ireland) following its acquisition of Synlab's main European competitor operations. It is one of the largest direct competitors to SYNLAB in routine and specialty clinical pathology.
• Eurofins Scientific SE: Eurofins is a global leader in bioanalytical testing and clinical diagnostics, operating one of the largest clinical laboratory networks in Europe. It directly competes with SYNLAB across routine and specialty testing, and acquired SYNLAB's Spanish operations in 2025 as part of 40 business combinations.
• ARUP Laboratories: ARUP Laboratories is a national reference laboratory owned by the University of Utah, specializing in esoteric and complex clinical testing across genetics, oncology, and infectious disease. It mirrors SYNLAB's reference and esoteric testing positioning in the U.S. market.
• Medicover AB: Medicover is a healthcare and diagnostics provider in Central and Eastern Europe with a growing Diagnostic Services division that includes the SYNLAB acquisition referenced in 2025 results. It is both a competitor and a partner in certain European markets, with overlapping clinical laboratory service offerings.
• Synlab AG (historical listed entity): Synlab AG was the historical listed parent of the broader SYNLAB Group (pre-Mars acquisition), headquartered in Munich and operating clinical laboratories across 30+ countries. The remaining listed/group activities serve as a direct historical and operational benchmark for SYNLAB Holding Deutschland GmbH.

Broad incumbents

• Quest Diagnostics: Quest Diagnostics is a leading U.S. provider of diagnostic information services, including routine clinical testing, advanced diagnostics, and anatomic pathology. As a broad incumbent, it operates a similar fee-for-service clinical laboratory model to SYNLAB, though primarily in North America.
• Laboratory Corporation of America (LabCorp): LabCorp is one of the world's largest clinical laboratory networks, offering routine and specialty diagnostics, drug development services, and point-of-care testing. While primarily U.S.-focused, it represents the global incumbent in clinical pathology and shares a comparable business model to SYNLAB.
• BioReference Laboratories (OPKO Health): BioReference Laboratories is a full-service clinical diagnostics laboratory with specialty expertise in reproductive genetics, oncology, and infectious disease. It competes with SYNLAB's specialty testing menu (e.g., neoBona NIPT, DPD-mutation testing), particularly in U.S. and international markets.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights6 records

Customer concentration

• Facebookfacebook.com/SYNLAB.deutschland.de
• LinkedInde.linkedin.com/company/synlab-holding-deutschland-gmbh
• Instagraminstagram.com/synlab_deutschland

Revenue estimate

Valuation estimate

Number of profiles

Profiles6 records

Subsidiaries1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about SYNLAB